Kranot Hishtalmut Le Morim Ve Gananot Havera Menahelet’s Teva Pharmaceuticals TEVA Stock Holding History

Kranot Hishtalmut Le Morim Ve Gananot Havera Menahelet’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$98.7M	Buy	+2,912,281	New	+$97M	4.05%	4
2023 Q1	–	Sell	-397,568	Closed	-$3.72M	–	101
2022 Q4	$3.72M	Hold	397,568	–	–	0.31%	76
2022 Q3	$3.1M	Hold	397,568	–	–	0.26%	82
2022 Q2	$2.96M	Hold	397,568	–	–	0.23%	79
2022 Q1	$3.71M	Hold	397,568	–	–	0.26%	74
2021 Q4	$3.19M	Hold	397,568	–	–	0.21%	87
2021 Q3	$3.87M	Hold	397,568	–	–	0.28%	78
2021 Q2	$3.94M	Buy	397,568 +17,274	+5%	+$183K	0.29%	77
2021 Q1	$4.39M	Buy	380,294 +212,433	+127%	+$2.44M	0.44%	57
2020 Q4	$1.62M	Buy	167,861 +7,279	+5%	+$69.7K	0.15%	65
2020 Q3	$1.45M	Buy	+160,582	New	+$1.7M	0.17%	58

Other funds holding TEVA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

HIIFS

Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return

Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return

MIFH

Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

LIM

Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Altshuler Shaham Tel Aviv, Israel $8.04B AUM 44.04% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Kranot Hishtalmut Le Morim Ve Gananot Havera Menahelet's TEVA Position: Q2 2026 in Review

Kranot Hishtalmut Le Morim Ve Gananot Havera Menahelet opened a new position in Teva Pharmaceuticals (TEVA) in Q2 2026: 2,912,281 shares worth $98.7M. The stake represents 4.05% of the portfolio and ranks #4 among its holdings. This is a return to the name: Kranot Hishtalmut Le Morim Ve Gananot Havera Menahelet previously reported a position in TEVA as recently as Q4 2022.

Kranot Hishtalmut Le Morim Ve Gananot Havera Menahelet first reported a position in TEVA in Q3 2020 and has held it in 11 quarters since. 451 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

Kranot Hishtalmut Le Morim Ve Gananot Havera Menahelet held 2,912,281 shares of Teva Pharmaceuticals worth $98.7M as of Q2 2026.
Teva Pharmaceuticals was a new Kranot Hishtalmut Le Morim Ve Gananot Havera Menahelet position in Q2 2026.
Teva Pharmaceuticals made up 4.05% of Kranot Hishtalmut Le Morim Ve Gananot Havera Menahelet's portfolio in Q2 2026, its #4 holding.
Kranot Hishtalmut Le Morim Ve Gananot Havera Menahelet first reported a position in Teva Pharmaceuticals in Q3 2020 and has held it in 11 quarters since.
451 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.

Based on Kranot Hishtalmut Le Morim Ve Gananot Havera Menahelet's 13F filing for Q2 2026, filed 5 Aug 2026.